Phase 1/2 Study of Intratumoral Injection of STX-001 in Advanced Solid Tumors as Monotherapy or in Combination With Pembrolizumab

Phase 1/2, Open-label, Multi-center, First-in-human Study of the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Anti-tumor Activity of STX-001 Delivered by Intratumoral Injection in Patients with Advanced Solid Tumors as a Monotherapy or in Combination with Pembrolizumab. The study now includes a monotherapy cohort targeting visceral lesions and a separate Phase 2 monotherapy cohort for advanced melanoma.

Trial Details

NCT ID
NCT06249048
Phase
PHASE1 / PHASE2
Sponsor
Strand Therapeutics Inc.
Status
RECRUITING
Cancer Type
Triple Negative (TNBC) Breast Cancer
Interventions
  • STX-001
  • Keytruda®
Locations (sample)
  • Scottsdale, Arizona, United States|33.50921,-111.89903
  • Beverly Hills, California, United States|34.07362,-118.40036
  • Cleveland, Ohio, United States|41.4995,-81.69541
  • Pittsburgh, Pennsylvania, United States|40.44062,-79.99589
  • Houston, Texas, United States|29.76328,-95.36327

Key Eligibility Criteria

  • ≥ 18 years of age at the time of screening.
  • Mentally competent and able to understand and sign the informed consent form (ICF).
  • Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.
  • Life expectancy of ≥ 12 weeks per the Investigator.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Triple Negative (TNBC) Breast Cancer Trials on Trialify →